Overseas Invited Speakers
Roy S. Herbst
Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine, USA
SY1 : Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer
Jin Mo Goo
Professor of Radiology, Department of Radiology, Seoul National University College of Medicine, Korea
SY4 : Globalization and Future of Lung Cancer Screening
David R. Gandara
Professor of Medicine Emeritus, Division of Hematology/Oncology, University of California, Davis School of Medicine
Director, Thoracic Oncology, Senior Advisor to the Director, UC Davis Comprehensive Cancer Center, USA
SY5 : Genome Medicine and Translational Research
Aaron Hata
Assistant Professor of Medicine at Massachusetts General Hospital, Principal Investigator in the MGH Center for Cancer Research, and Associate Member of the Broad Institute of Harvard and MIT, USA
SY5 : Genome Medicine and Translational Research
Roman Thomas
University of Cologne, Germany
SY6 : Basics in Cancer Biology: Overview of New Targets
Erik Thunnissen
Department of Pathology, Amsterdam University Medical Center, Netherland
SY2 : An Updated Approach to the Pathological Diagnosis of the Lung Cancer
Michael Thomas Milano
University of Rochester School of Medicine and Dentistry Department of Radiation Oncology and Wilmot Cancer Institute, USA
SY9 : Radiotherapy for Oligometastasis
Bruce E. Johnson
Chief Clinical Research Officer, Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School, USA
SY10 : Treatment of EGFR-Mutated and ALK-Fusion Positive Lung Cancer
Benjamin Solomon
Medical oncologist at the Peter MacCallum Cancer Centre Professor of Medicine at the University of Melbourne, Australia
SY13 : Treatment of Driver Mutation Positive Lung Cancer, Except for EGFR and ALK (include Ras/RAF)
Daniel Shao-Weng Tan
Senior Consultant of Division of Medical Oncology, Principal Investigator of Cancer Therapeutics Research Laboratory, Deputy Head of Division of Clinical Trials and Epidemiological Sciences, and Director of Experimental Cancer Therapeutics Unit (Phase I Unit), National Cancer Centre Singapore
Associate Professor, Duke-NUS Medical School
Senior Clinician-Scientist, Genome Institute of Singapore
Adjunct Investigator, Singapore Immunology Network, SIgN
SY13 : Treatment of Driver Mutation Positive Lung Cancer, Except for EGFR and ALK (include Ras/RAF)
Paul A. Bunn
Professor and James Dudley Chair at the University of Colorado Cancer Center, USA
SY14 : Lung Cancer Treatment During the COVID-19 Pandemic
Alain C. Borczuk
Professor of Pathology, Weill Cornell Medicine, USA
SY14 : Lung Cancer Treatment During the COVID-19 Pandemic
Solange Peters
Chair and Professor, Medical Oncology Full Professor, University Hospital of Lausanne, Switzerland
WS4 : Immunotherapy for SCLC
Natasha Rekhtman
Memorial Sloan Kettering Cancer Center, USA
WS10 : Neuroendocrine Tumors -Diagnosis and Treatment-